• Live
    • Audio Only
  • google plus
  • facebook
  • twitter
News > Mexico

Mexico Produces Test Batch of Russia's COVID Vaccine, Sputnik V

  • Mexico plans to bottle up to 20 million doses of Russia’s Sputnik V vaccine each month.

    Mexico plans to bottle up to 20 million doses of Russia’s Sputnik V vaccine each month. | Photo: Twitter/@The_Nation

Published 5 July 2021

The pharmaceutical company Laboratorios de Biológicos y Reactivos de México (Birmex) produced a test batch of the Russian vaccine Sputnik V against COVID-19, the Russian Direct Investment Fund (RDIF) informed on Monday.

The institution noted that Mexico thus becomes the first North American country to register the Russian drug, start its local production and thus be able to accelerate its national vaccination program.

Kirill Dmitriev, executive director of RDIF, commented that the production of the test batch in Mexico is an important step in the technology transfer process: "We hope that the batch will meet the most stringent requirements," he stressed.


Mexico To Get 24 Million Doses of Russia's Sputnik V Vaccine

He recalled that Sputnik V has been successfully used in Mexico for several months, demonstrating an excellent safety and efficacy profile.

According to the RDIF, to date, Sputnik V has been registered in 67 countries with a total combined population of more than 3.5 billion people.

"The Russian Direct Investment Fund and Mexican company @Birmex produced a test batch of #SputnikV vaccine. #Mexico has become the first country in North America to both register and launch local production of the @sputnikvaccine."

Data obtained by regulators during immunization in several nations, including Mexico, Argentina, Serbia, Bahrain, Hungary, United Arab Emirates and others, demonstrate that the Russian vaccine is among the safest and most effective against the SARS-CoV-2 coronavirus.

Sputnik V is based on a proven platform of human adenoviral vectors and uses two different vectors for the two injections in one vaccination course.

Its developers at the Gamaleya Center point out that this feature provides a longer period of immunity than vaccines that use the same delivery mechanism for both injections.

Post with no comments.